Bifogade filer
Xspray Pharma’s large shareholders and key individuals declare their intent to exercise TO5 warrants in November
Kurs
-0,29%
Likviditet
5,53 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-05-12 | N/A | Årsstämma |
| 2025-11-05 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-15 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-14 | - | X-dag ordinarie utdelning XSPRAY 0.00 SEK |
| 2025-05-13 | - | Årsstämma |
| 2025-05-07 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-12 | - | Bokslutskommuniké 2024 |
| 2024-11-06 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-07 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-22 | - | X-dag ordinarie utdelning XSPRAY 0.00 SEK |
| 2024-05-21 | - | Årsstämma |
| 2024-05-08 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-14 | - | Bokslutskommuniké 2023 |
| 2023-11-08 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-02 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | Extra Bolagsstämma 2023 |
| 2023-05-16 | - | Årsstämma |
| 2023-05-05 | - | X-dag ordinarie utdelning XSPRAY 0.00 SEK |
| 2023-05-04 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-15 | - | Bokslutskommuniké 2022 |
| 2022-11-09 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-05 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-20 | - | X-dag ordinarie utdelning XSPRAY 0.00 SEK |
| 2022-05-19 | - | Årsstämma |
| 2022-05-06 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-18 | - | Bokslutskommuniké 2021 |
| 2021-10-26 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-06 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-21 | - | X-dag ordinarie utdelning XSPRAY 0.00 SEK |
| 2021-05-20 | - | Årsstämma |
| 2021-05-06 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-11-20 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-31 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-15 | - | X-dag ordinarie utdelning XSPRAY 0.00 SEK |
| 2020-05-14 | - | Årsstämma |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-03-26 | - | Extra Bolagsstämma 2020 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-29 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | Årsstämma |
| 2019-05-17 | - | X-dag ordinarie utdelning XSPRAY 0.00 SEK |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-11-28 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-24 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-16 | - | X-dag ordinarie utdelning XSPRAY 0.00 SEK |
| 2018-05-14 | - | Årsstämma |
| 2018-05-14 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-20 | - | Extra Bolagsstämma 2017 |
| 2018-02-19 | - | Bokslutskommuniké 2017 |
| 2017-11-22 | - | Kvartalsrapport 2017-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Xspray Pharma has received written declarations of intent whereby owners of 53 percent of shares in the company state their intent to exercise warrants TO5 to subscribe for newly issued shares corresponding to their holdings of warrants of series TO5 during the subscription period 16-30 November 2023 for the subscription price 40.00 SEK per share. The company’s Chairman, CEO and CFO have also declared the same intent. All parties have confirmed that their holdings of TO5 warrants at least exceed the number that was allotted in connection to their participation in the rights issue in June this year which is expected to result in the exercise of over half the number of outstanding TO5 warrants.
”We are pleased with this news and the strong support our larger institutional owners have shown the company,” says Per Andersson, CEO of Xspray Pharma.
The outstanding warrants TO5 were allotted as part of the units that were subscribed for in connection to the preferential rights issue that Xspray Pharma made in June this year. If all outstanding TO5 are exercised, the company receives SEK 125.5 million in gross proceeds. The declarations of intent are expected to lead to the exercise of over half of the outstanding warrants of series TO5. The declarations of intent have been made by Flerie Invest, Östersjöstiftelsen, Ribbskottet AB, Fjärde AP-fonden, Tredje AP-fonden and Andra AP-fonden as well as Chairman Anders Ekblom, CEO Per Andersson and CFO Kerstin Hasselgren.
For further information, please contact:
Kerstin Hasselgren
Chief Financial Officer
Xspray Pharma AB
Mob: +46 (0) 70 311 16 83
E-mail: kerstin.hasselgren@xspray.com
About Xspray Pharma
Xspray Pharma AB (publ) is a pharmaceutical company with numerous product candidates in clinical development, utilizing its innovative, patented HyNap-technology to create improved versions of marketed protein kinase inhibitors (PKI), the largest oncology segment often with high drug prices. The company's goal is to become a market leader of enhanced PKIs for cancer treatment. Xspray Pharma's primary drug candidate, Dasynoc (XS004-dasatinib), is currently undergoing FDA review. It is an amorphous form of dasatinib, demonstrating bioequivalence at a 30% lower dose because of better solubility profile. Its compatibility with proton pump inhibitors (PPIs), commonly co-prescribed to chronic myeloid leukemia patients, provides a significant advantage. Xspray Pharma is building a robust product portfolio, including XS003-nilotinib (an optimized version of Tasigna®) and XS008-axitinib (an optimized version of Inlyta®).
Xspray Pharma’s shares are traded at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).
www.xspraypharma.com
This information is information that Xspray Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-11-09 13:33 CET.